The Drug-Induced Respiratory Disease Website
The broad term 'cardiotoxicity' encompasses several entities and patterns of cardiac injury including subclinical change in LVEF or cardiac biomarkers, cardiomyopathy, heart failure, AV heart block, conduction abnormalities, myocarditis, myocardial fibrosis, dysrrhythmias, pericarditis, pericardial effusion, tamponade, syncope, cardiac/cardiopulmonary arrest and/or valvular heart dysfunction or disease. Pulmonary edema and pleural effusion may be the annunciating signs and symptoms of cardiotoxicity (PMID 1403060). Cardiotoxicity is a significant hurdle of novel anticancer agent use including the immune checkpoint inhibitors (PMID 25210198, 25574894, 27732808, 29912044, 29980467, 30433897). Can be life-threatening or fatal (PMID 29980467)
Publications
Cardiotoxicity of anticancer treatments.
Nature reviews. Cardiology 2015 Sep;12;547-58 — 2015 Sep — 547-58
Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
Pediatric cardiology 2015 Aug;36;1112-9 — 2015 Aug — 1112-9
Evaluation of cardiotoxicity by tissue Doppler imaging in childhood leukemia survivors treated with low-dose anthracycline.
Pediatric cardiology 2015 Apr;36;862-6 — 2015 Apr — 862-6
Late cardiotoxic effects of anthracycline chemotherapy in childhood malignancies.
JPMA. The Journal of the Pakistan Medical Association 2008 Dec;58;683-7 — 2008 Dec — 683-7